帯状疱疹後神経痛（PHN）の世界市場レポート2025年

帯状疱疹後神経痛（PHN）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で9億9,000万米ドルに成長します。今後の成長を牽引する主要因としては、抗ウイルス療法やワクチンの使用拡大、慢性疼痛疾患の急増、先進ドラッグデリバリーシステムの導入拡大、臨床検査や研究開発への投資の増加、新たな治療選択肢に対する規制当局の承認の増加などが挙げられます。今後数年間に予想される新たな動向としては、神経障害性疼痛治療研究の進展、ドラッグデリバリーメカニズムの革新、技術主導型診断ソリューションの利用、臨床研究における人工知能の応用、非オピオイド鎮痛法の進化などが挙げられます。

慢性疼痛疾患の有病率の増加は、今後数年間の帯状疱疹後神経痛（PHN）市場の成長を促進すると予想されます。慢性疼痛とは、3ヶ月以上続く持続的または反復的な不快感を指し、多くの場合、病気やけがの通常の経過を超えて継続し、日常機能や生活の質に大きな影響を与えます。高齢者は関節炎や神経障害などの退行性疾患にかかりやすく、その結果、痛みが続くことが多いからです。帯状疱疹後神経痛は慢性疼痛研究の貴重なモデルであり、神経に関連した疼痛のメカニズムの理解を深め、長期的な治療戦略を評価するのに役立ちます。例えば、2024年1月、英国の政府部門であるOffice for Health Improvement and Disparitiesが発表した報告書によると、2023年には16歳以上の約18.4％が長期的な筋骨格系（MSK）疾患を有すると報告し、2022年の17.6％から増加しました。その結果、慢性疼痛疾患の発生率の増加がPHN市場の拡大に寄与しています。

帯状疱疹後神経痛（PHN）市場に参入する企業は、製品ラインナップを拡大し、競合優位性を獲得し、より効果的で忍容性の高い治療に対する大きなアンメットニーズに対応するため、規制当局の承認取得にますます注力するようになっています。薬事承認とは、医療当局から正式に許可されたもので、特定の医療適応症に対して薬や治療法の合法的な販売・投与を許可するものです。例えば、2023年2月、インドの製薬会社Zydus Lifesciences Ltd.は、米国食品医薬品局（FDA）より、1日1回服用のガバペンチン錠300mgと600mgのジェネリック医薬品を製造・販売する最終承認を取得しました。このガバペンチン錠は、水痘・帯状疱疹ウイルスの再活性化による神経障害によって引き起こされる神経障害性疼痛の一種であるPHNの治療に使用されます。通常、初日は300mgから開始し、2日目に600mg（300mgを1日2回）、3日目に900mg（300mgを1日3回）まで増量し、患者のニーズに応じて最大1日1,800mg（600mgを1日3回）まで漸増します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の帯状疱疹後神経痛（PHN）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の帯状疱疹後神経痛（PHN）市場：成長率分析
• 世界の帯状疱疹後神経痛（PHN）市場の実績：規模と成長、2019～2024年
• 世界の帯状疱疹後神経痛（PHN）市場の予測：規模と成長、2024～2029年、2034年
• 世界の帯状疱疹後神経痛（PHN）：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の帯状疱疹後神経痛（PHN）市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• パッチ
• 薬剤
• オピオイド
• 世界の帯状疱疹後神経痛（PHN）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の帯状疱疹後神経痛（PHN）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 外来手術センター
• その他
• 世界の帯状疱疹後神経痛（PHN）市場、パッチのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経皮ドラッグデリバリーパッチ
• ニコチンパッチ
• ホルモン補充療法パッチ
• 鎮痛パッチ
• 世界の帯状疱疹後神経痛（PHN）市場、薬剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 処方薬
• 市販薬（OTC）
• ジェネリック医薬品
• ブランド医薬品
• 生物製剤
• 世界の帯状疱疹後神経痛（PHN）市場、オピオイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 天然オピオイド
• 半合成オピオイド
• 合成オピオイド
• オピオイド鎮痛薬
• オピオイド拮抗薬

第7章 地域別・国別分析

• 世界の帯状疱疹後神経痛（PHN）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の帯状疱疹後神経痛（PHN）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 帯状疱疹後神経痛（PHN）市場：競合情勢
• 帯状疱疹後神経痛（PHN）市場：企業プロファイル
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Limited

第31章 その他の大手企業と革新的企業

• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Limited
• Mylan N.V.
• Mallinckrodt plc
• Merz Therapeutics GmbH
• Acorda Therapeutics Inc.
• Scilex Holding Company
• Elorac Inc.
• Lexicon Pharmaceuticals Inc.
• Oxford Cannabinoid Technologies Holdings plc
• Teikoku Pharma USA Inc.
• Acasti Pharma Inc.
• Flexion Therapeutics Inc.
• Haisco Pharmaceutical Group Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 帯状疱疹後神経痛（PHN）市場、2029年：新たな機会を提供する国
• 帯状疱疹後神経痛（PHN）市場、2029年：新たな機会を提供するセグメント
• 帯状疱疹後神経痛（PHN）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Postherpetic neuralgia (PHN) is a chronic nerve pain disorder that arises as a complication after an episode of herpes zoster (shingles). It is marked by ongoing, often intense pain in the area previously affected by the shingles rash, which can persist for months or even years after the skin has healed. PHN stems from nerve injury caused by the reactivation of the varicella-zoster virus and represents the most frequent complication of shingles, particularly among older individuals.

The primary treatment types for postherpetic neuralgia (PHN) include patches, medications, and opioids. Patches are transdermal drug delivery systems applied directly to the skin to ensure a consistent release of the drug into the bloodstream. These treatments are distributed via hospital pharmacies, retail pharmacies, and online platforms, and are utilized by hospitals, clinics, ambulatory surgical centers, and other healthcare providers.

The postherpetic neuralgia (PHN) market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The factors contributing to historical growth include a higher incidence of herpes zoster infections, an expanding elderly population, enhanced awareness among both patients and healthcare providers, rising demand for effective treatments targeting neuropathic pain, and increased healthcare spending.

The postherpetic neuralgia (PHN) market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. Key drivers for future growth include the expanded usage of antiviral therapies and vaccines, a surge in chronic pain conditions, greater implementation of advanced drug delivery systems, increased investment in clinical trials and R&D, and a rise in regulatory approvals for new treatment options. Emerging trends expected in the coming years involve progress in neuropathic pain treatment research, innovation in drug delivery mechanisms, the use of tech-driven diagnostic solutions, the application of artificial intelligence in clinical studies, and the evolution of non-opioid pain relief methods.

The increasing prevalence of chronic pain conditions is expected to drive the growth of the postherpetic neuralgia (PHN) market in the coming years. Chronic pain refers to persistent or recurring discomfort that lasts more than three months, often continuing beyond the normal course of an illness or injury and significantly affecting daily functioning and quality of life. This rising prevalence is largely attributed to the aging population, as older adults are more susceptible to degenerative diseases such as arthritis and neuropathy, which often result in ongoing pain. Postherpetic neuralgia serves as a valuable model for chronic pain research, helping to better understand nerve-related pain mechanisms and assess long-term treatment strategies. For example, in January 2024, a report published by the Office for Health Improvement and Disparities, a UK-based government department, indicated that approximately 18.4% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition in 2023, up from 17.6% in 2022. As a result, the growing incidence of chronic pain conditions is contributing to the expansion of the PHN market.

Companies involved in the postherpetic neuralgia (PHN) market are increasingly focusing on securing regulatory approvals to broaden their product offerings, gain a competitive edge, and address the substantial unmet need for more effective and better-tolerated treatments. Regulatory approvals refer to official permissions granted by health authorities, allowing a medication or therapy to be legally marketed and administered for a specific medical indication. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, received final approval from the United States Food and Drug Administration to produce and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg doses, indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are used to treat PHN, a type of neuropathic pain caused by nerve damage due to reactivation of the varicella-zoster virus. Typical dosing begins at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with potential titration up to a maximum of 1800 mg per day (600 mg three times daily) based on patient needs.

In September 2023, Adalvo Limited, a Malta-based pharmaceutical company specializing in service-based pharmaceutical partnerships, teamed up with Lotus Pharmaceutical Co. Ltd. to introduce Gabapentin ER tablets in South Korea. This strategic collaboration is intended to improve patient access to innovative and effective therapies by launching Gabapentin ER in the South Korean market, thereby reinforcing the companies' presence in the neurology sector and expanding their portfolios with high-value pharmaceutical offerings. Lotus Pharmaceutical Co., Ltd. is a Taiwan-based pharmaceutical firm that manufactures medications, including those for the treatment of postherpetic neuralgia (PHN).

Major players in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Lexicon Pharmaceuticals Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Acasti Pharma Inc., Flexion Therapeutics Inc., Haisco Pharmaceutical Group Co. Ltd., Shanghai SIMR Biotechnology Co. Ltd.

North America was the largest region in the postherpetic neuralgia (PHN) market in 2024. The regions covered in postherpetic neuralgia (PHN) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the postherpetic neuralgia (PHN) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The postherpetic neuralgia (PHN) market includes revenues earned by entities by providing services such as medical consultation, pain management services, topical treatment application, physical therapy and nerve block or injections. The market value includes the value of related goods sold by the service provider or included within the service offering. The postherpetic neuralgia (PHN) market consists of sales of anticonvulsants, amitriptyline, tramadol, oxycodone, and nortriptyline. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Postherpetic Neuralgia (PHN) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on postherpetic neuralgia (phn) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for postherpetic neuralgia (phn) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The postherpetic neuralgia (phn) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Patches; Drugs; Opioids
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End Users: Hospitals; Clinics; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Patches: Transdermal Drug Delivery Patches; Nicotine Patches; Hormone Replacement Therapy Patches; Analgesic Patches; Orthopedic Support Patches
• 2) By Drugs: Prescription Drugs; Over-The-Counter (OTC) Drugs; Generic Drugs; Branded Drugs; Biologic Drugs
• 3) By Opioids: Natural Opioids; Semi-Synthetic Opioids; Synthetic Opioids; Opioid Analgesics; Opioid Antagonists
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Postherpetic Neuralgia (PHN) Market Characteristics

3. Postherpetic Neuralgia (PHN) Market Trends And Strategies

4. Postherpetic Neuralgia (PHN) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Postherpetic Neuralgia (PHN) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Postherpetic Neuralgia (PHN) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Postherpetic Neuralgia (PHN) Market Growth Rate Analysis
• 5.4. Global Postherpetic Neuralgia (PHN) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Postherpetic Neuralgia (PHN) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Postherpetic Neuralgia (PHN) Total Addressable Market (TAM)

6. Postherpetic Neuralgia (PHN) Market Segmentation

• 6.1. Global Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patches
• Drugs
• Opioids
• 6.2. Global Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global Postherpetic Neuralgia (PHN) Market, Sub-Segmentation Of Patches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transdermal Drug Delivery Patches
• Nicotine Patches
• Hormone Replacement Therapy Patches
• Analgesic Patches
• 6.5. Global Postherpetic Neuralgia (PHN) Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription Drugs
• Over-The-Counter (OTC) Drugs
• Generic Drugs
• Branded Drugs
• Biologic Drugs
• 6.6. Global Postherpetic Neuralgia (PHN) Market, Sub-Segmentation Of Opioids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natural Opioids
• Semi-Synthetic Opioids
• Synthetic Opioids
• Opioid Analgesics
• Opioid Antagonists

7. Postherpetic Neuralgia (PHN) Market Regional And Country Analysis

• 7.1. Global Postherpetic Neuralgia (PHN) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Postherpetic Neuralgia (PHN) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Postherpetic Neuralgia (PHN) Market

• 8.1. Asia-Pacific Postherpetic Neuralgia (PHN) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Postherpetic Neuralgia (PHN) Market

• 9.1. China Postherpetic Neuralgia (PHN) Market Overview
• 9.2. China Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Postherpetic Neuralgia (PHN) Market

• 10.1. India Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Postherpetic Neuralgia (PHN) Market

• 11.1. Japan Postherpetic Neuralgia (PHN) Market Overview
• 11.2. Japan Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Postherpetic Neuralgia (PHN) Market

• 12.1. Australia Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Postherpetic Neuralgia (PHN) Market

• 13.1. Indonesia Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Postherpetic Neuralgia (PHN) Market

• 14.1. South Korea Postherpetic Neuralgia (PHN) Market Overview
• 14.2. South Korea Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Postherpetic Neuralgia (PHN) Market

• 15.1. Western Europe Postherpetic Neuralgia (PHN) Market Overview
• 15.2. Western Europe Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Postherpetic Neuralgia (PHN) Market

• 16.1. UK Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Postherpetic Neuralgia (PHN) Market

• 17.1. Germany Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Postherpetic Neuralgia (PHN) Market

• 18.1. France Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Postherpetic Neuralgia (PHN) Market

• 19.1. Italy Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Postherpetic Neuralgia (PHN) Market

• 20.1. Spain Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Postherpetic Neuralgia (PHN) Market

• 21.1. Eastern Europe Postherpetic Neuralgia (PHN) Market Overview
• 21.2. Eastern Europe Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Postherpetic Neuralgia (PHN) Market

• 22.1. Russia Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Postherpetic Neuralgia (PHN) Market

• 23.1. North America Postherpetic Neuralgia (PHN) Market Overview
• 23.2. North America Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Postherpetic Neuralgia (PHN) Market

• 24.1. USA Postherpetic Neuralgia (PHN) Market Overview
• 24.2. USA Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Postherpetic Neuralgia (PHN) Market

• 25.1. Canada Postherpetic Neuralgia (PHN) Market Overview
• 25.2. Canada Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Postherpetic Neuralgia (PHN) Market

• 26.1. South America Postherpetic Neuralgia (PHN) Market Overview
• 26.2. South America Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Postherpetic Neuralgia (PHN) Market

• 27.1. Brazil Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Postherpetic Neuralgia (PHN) Market

• 28.1. Middle East Postherpetic Neuralgia (PHN) Market Overview
• 28.2. Middle East Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Postherpetic Neuralgia (PHN) Market

• 29.1. Africa Postherpetic Neuralgia (PHN) Market Overview
• 29.2. Africa Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Postherpetic Neuralgia (PHN) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Postherpetic Neuralgia (PHN) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Postherpetic Neuralgia (PHN) Market Competitive Landscape And Company Profiles

• 30.1. Postherpetic Neuralgia (PHN) Market Competitive Landscape
• 30.2. Postherpetic Neuralgia (PHN) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

31. Postherpetic Neuralgia (PHN) Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. Daiichi Sankyo Company Limited
• 31.3. Sun Pharmaceutical Industries Limited
• 31.4. Mylan N.V.
• 31.5. Mallinckrodt plc
• 31.6. Merz Therapeutics GmbH
• 31.7. Acorda Therapeutics Inc.
• 31.8. Scilex Holding Company
• 31.9. Elorac Inc.
• 31.10. Lexicon Pharmaceuticals Inc.
• 31.11. Oxford Cannabinoid Technologies Holdings plc
• 31.12. Teikoku Pharma USA Inc.
• 31.13. Acasti Pharma Inc.
• 31.14. Flexion Therapeutics Inc.
• 31.15. Haisco Pharmaceutical Group Co. Ltd.

32. Global Postherpetic Neuralgia (PHN) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Postherpetic Neuralgia (PHN) Market

34. Recent Developments In The Postherpetic Neuralgia (PHN) Market

35. Postherpetic Neuralgia (PHN) Market High Potential Countries, Segments and Strategies

• 35.1 Postherpetic Neuralgia (PHN) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Postherpetic Neuralgia (PHN) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Postherpetic Neuralgia (PHN) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer